A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
IMIQUIMOD - A TOLL LIKE RECEPTOR 7 AGONIST - IS AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
2020
Qeios
Preserved Fulltext
According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (T NF)-α, interleukin IL-2R and IL-6). T he total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through T LRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates T LR 7 and can be used
doi:10.32388/u1e9ge
fatcat:ll7gasrgrzdonjd5kbjqg7vweq